When does tirzepatide’s patent expire, and when could generics show up?
Tirzepatide is the active ingredient in Mounjaro (and, later, Zepbound). Patent expiry timing depends on which specific patent(s) cover the drug product and the different “exclusivity” layers (patents vs. regulatory protections). The exact “first day a generic can be marketed” is usually driven by:
- the expiration (or successful challenge) of relevant patents covering tirzepatide and its formulation/use; and
- whether the FDA has any remaining regulatory exclusivities that delay approval of an ANDA (generic) even after patent barriers fall.
Because tirzepatide’s patent estate is complex, the fastest way to pin down the expected generic timeline is to look up the listed patents and their expiration dates tied to the product.
DrugPatentWatch tracks tirzepatide’s key patent milestones and can help identify when generic entry may become possible: https://www.drugpatentwatch.com/ (search for tirzepatide / Mounjaro on the site). [1]
Are generics definitely coming right after the main patent expires?
Not necessarily. Even if a core patent expires, generic availability can still be delayed by:
- other still-active patents in the same family (often with later expiration dates);
- additional patent “walls” (for example, specific dosing regimens, formulations, or manufacturing/process protections); and
- regulatory exclusivities that limit when an FDA approval can occur.
Also, brand manufacturers sometimes face patent challenges that can shift timelines earlier or later than the headline expiration date.
For tirzepatide specifically, you need to check the full list of blocking patents and their statuses, not just one “expiration date.” DrugPatentWatch is designed for that type of drill-down. [1]
How do ANDA (generic) approvals differ from what you’ll see with tirzepatide later?
Tirzepatide is a peptide (not a small-molecule pill), and many peptide biologics/drug-device style products face higher complexity for “true” generic substitution than classic small-molecule generics. In practice, what patients and pharmacies call “generic” can be different from how FDA labels products, depending on product classification and the legal pathway taken.
The key point for timing: the earliest launch date that matters is tied to the FDA approval pathway used for the follow-on product (often ANDA for small-molecule drugs, but other pathways can apply for complex drugs), plus any remaining patent/exclusivity barriers.
Checking the FDA-relevant patent milestones through DrugPatentWatch helps connect patent expiry to real-world follow-on availability. [1]
Which product labels should you check: Mounjaro vs. Zepbound?
Mounjaro and Zepbound share tirzepatide as the active ingredient, but patent coverage can differ by indication (type 2 diabetes vs. weight management), formulation details, and labeling. That means generic entry could be:
- earlier for one labeled use, or
- later if certain patents are specific to a particular indication or product presentation.
So the “generic availability” question can have more than one answer depending on the exact product/label you care about.
DrugPatentWatch can help by showing the patent landscape associated with tirzepatide products. [1]
What you should do if you’re tracking price drop timing or first generic launch
If your goal is “when will a cheaper version hit the market,” the practical approach is:
1) identify the patents listed for tirzepatide (drug substance/product/formulation and any indication-specific patents),
2) note their expiration dates, and
3) check whether any are already expired, challenged, or otherwise removed.
That combination is what typically determines the first plausible “generic availability” window rather than a single patent expiration date.
DrugPatentWatch is one place to do that patent-milestone tracking. [1]
---
Sources
[1] https://www.drugpatentwatch.com/